Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for BRTX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2011. Start Trial.
Date Value
March 31, 2026 0.9684M
December 31, 2025 2.401M
September 30, 2025 1.998M
June 30, 2025 2.132M
March 31, 2025 2.367M
December 31, 2024 1.533M
September 30, 2024 0.9368M
June 30, 2024 2.973M
March 31, 2024 -4.928M
December 31, 2023 -0.0848M
September 30, 2023 -0.0214M
June 30, 2023 0.819M
March 31, 2023 2.539M
December 31, 2022 -3.323M
September 30, 2022 -9.909M
June 30, 2022 -0.1377M
March 31, 2022 -0.1096M
December 31, 2021 -0.0307M
September 30, 2021 0.00
June 30, 2021 0.00
March 31, 2021 0.00
December 31, 2020 0.00
September 30, 2020 0.00
June 30, 2020 0.00
March 31, 2020 0.00
Date Value
December 31, 2019 0.00
September 30, 2019 -0.0063M
June 30, 2019 -0.0294M
March 31, 2019 0.00
December 31, 2018 0.00
September 30, 2018 0.00
June 30, 2018 -0.0129M
March 31, 2018 0.00
December 31, 2017 -0.0036M
September 30, 2017 0.00
June 30, 2017 0.00
March 31, 2017 0.00
December 31, 2016 -0.0068M
September 30, 2016 -0.0307M
June 30, 2016 -0.0613M
March 31, 2016 -0.0899M
December 31, 2015 -0.0476M
September 30, 2015 -0.2086M
June 30, 2015 -0.0597M
March 31, 2015 -0.1672M
December 31, 2014 -0.1668M
September 30, 2014 -0.0015M
June 30, 2014 0.00
March 31, 2014 0.001M
December 31, 2013 -0.0112M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Myriad Genetics, Inc. -3.20M
CareDx, Inc. 280.59M
Natera, Inc. -63.43M
Exagen, Inc. -0.543M
Sera Prognostics, Inc. 6.394M